Posted on 7/31/18
Antares Pharma to Report Second Quarter 2018 Financial and Operating Results
EWING, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2018 financial results and recent . . .
Posted on 7/31/18
General Electric: The Reasons To Buy Now Are Aviation And Healthcare
SummaryGeneral Electric's two best divisions, which are Aviation and Healthcare, continued to shine in the second quarter.Buying GE shares this year will set investors up to . . .
Posted on 7/31/18
On the Back of a Solid Quarter, Celgene Looks Ahead
Celgene (NASDAQ:CELG) posted solid second-quarter results thanks to ever-expanding sales of blood cancer drug Revlimid, but investors should be equally focused on the biotech's potential as . . .
Posted on 7/31/18
FOX Rehabilitation Joins enTouch Network in Pennsylvania and New Jersey
PreparedHealth today announced that FOX Rehabilitation has joined the enTouch Network to streamline health-related communication around their patients. FOX Rehabilitation is a clinician-owned and operated professional . . .
Posted on 7/31/18
Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions
MORRIS PLAINS, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced . . .
Posted on 7/30/18
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope
Daiichi Sankyo Company, Limited and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo's proprietary ADC . . .
Posted on 7/30/18
Johnson & Johnson Consumer To Acquire Zarbee's
Johnson & Johnson Consumer Inc. announced today that it has entered into a definitive agreement to acquire Zarbee's, Inc., a privately held company that is a . . .
Posted on 7/30/18
Merck & Co Inc. (MRK) CEO Ken Frazier on Q2 2018 Results - Earnings Call Transcript
Merck & Co Inc. (NYSE:MRK) Q2 2018 Earnings Conference Call July 27, 2018 8:00 AM ETExecutivesTeri Loxam - IR & Global CommunicationsKen Frazier - Chairman and . . .
Posted on 7/30/18
Why Pfizer's Q2 Earnings Results Might Be Weaker Than You'd Like
When Pfizer (NYSE:PFE) reported its first-quarter results in May, there were things to like -- but things to dislike, too. The big pharma company's earnings soared . . .
Posted on 7/30/18
Why Celgene Is Looking Less Risky and More Attractive
Yes, Celgene (NASDAQ:CELG) is probably the riskiest big biotech on the planet. The company depends on one drug -- Revlimid -- for 64% of its revenue. . . .
Posted on 7/30/18
Can Celgene’s Most Important Drugs Keep Growing?
Celgene Corp. (NASDAQ:CELG) markets four billion-dollar blockbuster medicines, but only two were behind its stellar sales and profit performance in the second quarter. Sales of Revlimid . . .
Posted on 7/29/18
Aquestive Therapeutics Closes IPO
Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the closing of its . . .
Posted on 7/29/18
Logic Biosciences Announces International Award for LBS-101 Program
NEWARK, N.J.--(BUSINESS WIRE)--Logic Biosciences, Inc., a development-stage pharmaceutical company, today announced that its lead product candidate, LBS-101, has been recognized with an Innovation in Oral Care . . .
Posted on 7/29/18
Chembio Diagnostics Announces Collaboration with FIND
MEDFORD, N.Y. and GENEVA, July 28, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic testing, today announced a collaboration with the . . .
Posted on 7/26/18
Vaccinex Readies $45 Million U.S. IPO
SummaryVaccinex has filed proposed terms for a $45 million IPO of its common stock.The firm is developing potential treatments for Huntington's Disease and non-small cell lung . . .
Posted on 7/25/18
Pfizer: Keep On Reinvesting Dividends
SummaryDonald Trump calls out the company on its price hikes.Shares not adversely affected.The dividend still looks strong.This idea was discussed in more depth with members of . . .
Posted on 7/25/18
Aquestive Therapeutics Prices IPO
Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the pricing of its . . .
Posted on 7/24/18
Edgewater Health Selects TenEleven as Their EHR Partner
BUFFALO, N.Y.--(BUSINESS WIRE)--Edgewater Health seeks to provide care for the whole person to the clients they serve in Gary and Northwest Indiana. After struggling with multiple . . .
Posted on 7/24/18
Quest Diagnostics Reports Second Quarter 2018 Financial Results
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the second quarter ended June 30, 2018."Once again, . . .
Posted on 7/24/18
Pfizer & Eli Lilly Obtain Potential Pain Alternative For Treating Osteoarthritis Pain
SummaryPfizer and its partner Eli Lilly announced positive phase 3 results treating patients with osteoarthritis of the knee or hip using tanezumab.The positive phase 3 results . . .
Posted on 7/24/18
Better Buy: Gilead Sciences, Inc. vs. Celgene
Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) have both produced tremendous gains for long-term shareholders. Over a three-year period leading up to mid-2015, both of . . .
Posted on 7/24/18
Should GlaxoSmithKline Break Up?
British pharma giant GlaxoSmithKline (NYSE:GSK) is reportedly exploring a breakup of its consumer healthcare and pharma/vaccine units into separate businesses. The drugmaker's management is under pressure . . .
Posted on 7/23/18
Anima Biotech Announces an Exclusive Collaboration With Lilly
Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics . . .
Posted on 7/23/18
Bridge Medicines Enters Agreement with Memorial Sloan Kettering
Bridge Medicines announced today an agreement with Memorial Sloan Kettering (MSK) to develop a platform designed to deliver drugs specifically to the kidney. The first disease . . .
Posted on 7/23/18
Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers
DURHAM, N.C.--(BUSINESS WIRE)--Bioventus, a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program . . .

